Stay updated with breaking news from Adjuvant Setting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lumateperone is now the only FDA-approved drug for depressive episodes associated with bipolar I or II disorder in adults, as monotherapy or an adjunct to lithium or valproate.
Adding a regular yoga regimen to standard therapy can reduce symptoms and improve quality of life in patients with frequent fainting spells, or vasovagal syncope (VVS).
A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.
Metformin as adjuvant therapy did not improve invasive disease-free survival or overall survival rates, regardless of hormone receptor status.
KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC MelanomaKEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III DiseaseKENILWORTH, N.J.-...